These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 38219146)

  • 1. DNA polymerase ε and δ variants drive mutagenesis in polypurine tracts in human tumors.
    Ostroverkhova D; Tyryshkin K; Beach AK; Moore EA; Masoudi-Sobhanzadeh Y; Barbari SR; Rogozin IB; Shaitan KV; Panchenko AR; Shcherbakova PV
    Cell Rep; 2024 Jan; 43(1):113655. PubMed ID: 38219146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. POLE and POLD1 germline exonuclease domain pathogenic variants, a rare event in colorectal cancer from the Middle East.
    Siraj AK; Bu R; Iqbal K; Parvathareddy SK; Masoodi T; Siraj N; Al-Rasheed M; Kong Y; Ahmed SO; Al-Obaisi KAS; Victoria IG; Arshad M; Al-Dayel F; Abduljabbar A; Ashari LH; Al-Kuraya KS
    Mol Genet Genomic Med; 2020 Aug; 8(8):e1368. PubMed ID: 32567205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer.
    Church DN; Briggs SE; Palles C; Domingo E; Kearsey SJ; Grimes JM; Gorman M; Martin L; Howarth KM; Hodgson SV; ; Kaur K; Taylor J; Tomlinson IP
    Hum Mol Genet; 2013 Jul; 22(14):2820-8. PubMed ID: 23528559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High mutational burden in colorectal carcinomas with monoallelic POLE mutations: absence of allelic loss and gene promoter methylation.
    Hühns M; Nürnberg S; Kandashwamy KK; Maletzki C; Bauer P; Prall F
    Mod Pathol; 2020 Jun; 33(6):1220-1231. PubMed ID: 31857678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nucleotide selectivity defect and mutator phenotype conferred by a colon cancer-associated DNA polymerase δ mutation in human cells.
    Mertz TM; Baranovskiy AG; Wang J; Tahirov TH; Shcherbakova PV
    Oncogene; 2017 Aug; 36(31):4427-4433. PubMed ID: 28368425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proofreading the way: immune checkpoint inhibitors in polymerase ε/polymerase δ (POLE/POLD1)-altered colorectal cancer.
    Cecchini M; Sundar R
    Ann Oncol; 2024 Jul; 35(7):582-584. PubMed ID: 38910015
    [No Abstract]   [Full Text] [Related]  

  • 7. POLE/POLD1 mutation and tumor immunotherapy.
    Ma X; Dong L; Liu X; Ou K; Yang L
    J Exp Clin Cancer Res; 2022 Jul; 41(1):216. PubMed ID: 35780178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low frequency of POLD1 and POLE exonuclease domain variants in patients with multiple colorectal polyps.
    Elsayed FA; Tops CMJ; Nielsen M; Ruano D; Vasen HFA; Morreau H; J Hes F; van Wezel T
    Mol Genet Genomic Med; 2019 Apr; 7(4):e00603. PubMed ID: 30827058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological and mutational analyses of colorectal cancer with mutations in the POLE gene.
    Hino H; Shiomi A; Kusuhara M; Kagawa H; Yamakawa Y; Hatakeyama K; Kawabata T; Oishi T; Urakami K; Nagashima T; Kinugasa Y; Yamaguchi K
    Cancer Med; 2019 Aug; 8(10):4587-4597. PubMed ID: 31240875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the basis of heterogeneity of cancer aggressiveness among the mutated POLE variants.
    Selves J; de Castro E Gloria H; Brunac AC; Saffi J; Guimbaud R; Brousset P; Hoffmann JS
    Life Sci Alliance; 2024 Jan; 7(1):. PubMed ID: 37891003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interpretation of somatic POLE mutations in endometrial carcinoma.
    León-Castillo A; Britton H; McConechy MK; McAlpine JN; Nout R; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Bosse T; Church DN; Gilks CB
    J Pathol; 2020 Mar; 250(3):323-335. PubMed ID: 31829442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. POLE Mutation Spectra Are Shaped by the Mutant Allele Identity, Its Abundance, and Mismatch Repair Status.
    Hodel KP; Sun MJS; Ungerleider N; Park VS; Williams LG; Bauer DL; Immethun VE; Wang J; Suo Z; Lu H; McLachlan JB; Pursell ZF
    Mol Cell; 2020 Jun; 78(6):1166-1177.e6. PubMed ID: 32497495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. POLE and POLD1 screening in 155 patients with multiple polyps and early-onset colorectal cancer.
    Esteban-Jurado C; Giménez-Zaragoza D; Muñoz J; Franch-Expósito S; Álvarez-Barona M; Ocaña T; Cuatrecasas M; Carballal S; López-Cerón M; Marti-Solano M; Díaz-Gay M; van Wezel T; Castells A; Bujanda L; Balmaña J; Gonzalo V; Llort G; Ruiz-Ponte C; Cubiella J; Balaguer F; Aligué R; Castellví-Bel S
    Oncotarget; 2017 Apr; 8(16):26732-26743. PubMed ID: 28423643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solving the enigma of POLD1 p.V295M as a potential cause of increased cancer risk.
    Mur P; Magraner-Pardo L; García-Mulero S; Díez-Villanueva A; Del Valle J; Ezquerro E; Lázaro C; Capellá G; Moreno V; Sanz-Pamplona R; Pons T; Valle L
    Eur J Hum Genet; 2022 Apr; 30(4):485-489. PubMed ID: 34285382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance.
    Bellido F; Pineda M; Aiza G; Valdés-Mas R; Navarro M; Puente DA; Pons T; González S; Iglesias S; Darder E; Piñol V; Soto JL; Valencia A; Blanco I; Urioste M; Brunet J; Lázaro C; Capellá G; Puente XS; Valle L
    Genet Med; 2016 Apr; 18(4):325-32. PubMed ID: 26133394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.
    Temko D; Van Gool IC; Rayner E; Glaire M; Makino S; Brown M; Chegwidden L; Palles C; Depreeuw J; Beggs A; Stathopoulou C; Mason J; Baker AM; Williams M; Cerundolo V; Rei M; Taylor JC; Schuh A; Ahmed A; Amant F; Lambrechts D; Smit VT; Bosse T; Graham TA; Church DN; Tomlinson I
    J Pathol; 2018 Jul; 245(3):283-296. PubMed ID: 29604063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of POLE and POLD1 in familial cancer.
    Mur P; García-Mulero S; Del Valle J; Magraner-Pardo L; Vidal A; Pineda M; Cinnirella G; Martín-Ramos E; Pons T; López-Doriga A; Belhadj S; Feliubadaló L; Munoz-Torres PM; Navarro M; Grau E; Darder E; Llort G; Sanz J; Ramón Y Cajal T; Balmana J; Brunet J; Moreno V; Piulats JM; Matías-Guiu X; Sanz-Pamplona R; Aligué R; Capellá G; Lázaro C; Valle L
    Genet Med; 2020 Dec; 22(12):2089-2100. PubMed ID: 32792570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational processes of distinct POLE exonuclease domain mutants drive an enrichment of a specific TP53 mutation in colorectal cancer.
    Fang H; Barbour JA; Poulos RC; Katainen R; Aaltonen LA; Wong JWH
    PLoS Genet; 2020 Feb; 16(2):e1008572. PubMed ID: 32012149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. POLD1 and POLE Gene Mutations in Jewish Cohorts of Early-Onset Colorectal Cancer and of Multiple Colorectal Adenomas.
    Rosner G; Gluck N; Carmi S; Bercovich D; Fliss-Issakov N; Ben-Yehoyada M; Aharon-Caspi S; Kellerman E; Strul H; Shibolet O; Kariv R
    Dis Colon Rectum; 2018 Sep; 61(9):1073-1079. PubMed ID: 30086056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas.
    Palles C; Cazier JB; Howarth KM; Domingo E; Jones AM; Broderick P; Kemp Z; Spain SL; Guarino E; Salguero I; Sherborne A; Chubb D; Carvajal-Carmona LG; Ma Y; Kaur K; Dobbins S; Barclay E; Gorman M; Martin L; Kovac MB; Humphray S; ; ; Lucassen A; Holmes CC; Bentley D; Donnelly P; Taylor J; Petridis C; Roylance R; Sawyer EJ; Kerr DJ; Clark S; Grimes J; Kearsey SE; Thomas HJ; McVean G; Houlston RS; Tomlinson I
    Nat Genet; 2013 Feb; 45(2):136-44. PubMed ID: 23263490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.